Parkines

Quick links to important sections

Parkines

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Parkines

Property Description
Active Ingredient Trihexyphenidyl hydrochloride (Benzhexol)
Form Oral Preparation (Tablet)
Pharmacological Class Central Anticholinergic Agent
Common Use Helps mitigate symptoms like tremor and muscle stiffness
Origin Synthetic Compound

What Type of Medicine is Parkines?

Parkines is the trade designation for a single-ingredient product whose active ingredient is Trihexyphenidyl hydrochloride. This medication is classified as a central Anticholinergic agent. Trihexyphenidyl, sometimes referred to as Benzhexol, is a synthetic compound, positioning it as a manufactured pharmaceutical rather than a natural derivative. It is typically supplied as a prescription drug (Rx), reflecting its potent action and the necessity of medical oversight for appropriate use. The compound is clinically recognized for its modulatory effects on the nervous system, placing it within the broader class of Antiparkinsonian agents.


Composition and General Purpose of Trihexyphenidyl

Parkines is an oral preparation primarily formulated as a tablet, intended for administration via the oral route. The product is composed exclusively of the active ingredient Trihexyphenidyl hydrochloride combined with various solid pharmaceutical excipients, which are inactive components like binders and fillers necessary to create the final solid dosage form.

The general purpose of this Anticholinergic agent is to functionally modulate excessive nerve signals that contribute to specific movement difficulties. Trihexyphenidyl helps to re-establish a critical balance between the brain's cholinergic and dopaminergic system output. This action provides the general benefit of mitigating symptoms like muscle stiffness, specific types of tremor, and involuntary movements (dyskinesia) that result from such neurological imbalances.

What side effects are possible with Parkines?

Possible Side Effects and Safety Information

The adverse reaction profile of Trihexyphenidyl hydrochloride (Parkines) is consistent with its action as a central anticholinergic agent. The official regulatory safety documentation classifies adverse effects by system and frequency.

High-Incidence Adverse Reactions

Official labeling indicates that 30 to 50 percent of all patients may experience certain minor side effects, often becoming less pronounced as treatment continues. These reactions include dryness of the mouth, blurring of vision, dizziness, mild nausea, and nervousness.

System-Organ Classes and Less Common Effects

Safety data lists effects across several body systems. Gastrointestinal disorders may include constipation and, rarely, paralytic ileus. Nervous system disorders may involve drowsiness, weakness, or, in isolated instances, mental confusion or hallucinations. Ophthalmic effects include dilation of the pupil and the potential for increased intraocular tension.

Serious Adverse Reactions and Time-Related Patterns

Serious adverse reactions reported in regulatory sources include angle-closure glaucoma, which can potentially lead to blindness, particularly associated with long-term treatment. A potentially fatal condition, Neuroleptic Malignant Syndrome (NMS), has been reported in association with abrupt discontinuation or dose reduction. The drug may also aggravate the symptoms of Tardive Dyskinesia.

Population-Specific Safety Considerations

Caution is advised in several groups: geriatric patients (over age 60) may exhibit increased sensitivity. Warnings also apply to patients with pre-existing glaucoma or obstructive diseases of the gastrointestinal or genitourinary tracts. Furthermore, due to the risk of fatal hyperthermia and inability to sweat, caution is necessary during exercise or use in hot weather.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Parkines

This section summarizes the officially documented manifestations and required emergency actions for an overdose of Trihexyphenidyl (Parkines), strictly based on governmental regulatory sources.

Overdose Scope

Property Official Regulatory Statement/Entity
Documented overdose presentations The clinical picture is characterized by signs of central and peripheral anticholinergic toxidrome, including delirium, hallucinations, confusion, mydriasis (dilated pupils), hot/dry skin, dry mouth, and urinary retention.
Physiological systems affected Central Nervous System (CNS): Excitation, stupor, coma, seizures, respiratory depression. Cardiovascular System: Tachycardia, hypertension, cardiac arrhythmias, circulatory failure.
Population-specific overdose notes Overdose effects may be exaggerated in the elderly population. Children are noted to have an increased risk of severe symptoms.
When immediate medical help is required Seek immediate medical attention for all suspected cases. Hospitalization is required for continuous monitoring and management of life-threatening symptoms.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement/Entity
Severity classification Overdose can lead to severe or life-threatening outcomes, including respiratory and circulatory failure.
Overdose-context constraints Continuous ECG monitoring is required for at least 24 hours. The drug has no universal antidote, but Physostigmine may be considered for severe anticholinergic effects in a controlled hospital setting.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with severe anticholinergic signs like delirium, mydriasis, hyperpyrexia, and urinary retention.
  • Severe outcomes include cardiac arrhythmias, circulatory failure, and respiratory depression.
  • Seek immediate medical attention and professional care immediately; supportive measures like gastric decontamination (lavage/activated charcoal) are documented.

Connection to the overall overdose profile (2–4 sentences): Regulatory documentation defines the Trihexyphenidyl overdose profile by detailing severe clinical manifestations that stem from excessive anticholinergic activity. This framework underscores the risk of life-threatening cardiovascular and CNS outcomes, thereby mandating the requirement to seek immediate medical attention and undergo structured, continuous monitoring and supportive care procedures in a hospital environment.

Therapeutic Uses of Parkines

Parkines (Trihexyphenidyl) is a medication that may be part of symptomatic management for conditions that cause disruption to normal movement and muscle control.

The medication is considered relevant across domains where additional symptomatic support is needed, addressing specific symptom clusters that interfere with daily functioning. Its primary applications include managing core motor symptoms of Parkinson's disease (such as rigidity and resting tremor), controlling drug-induced Extrapyramidal Symptoms (EPS), and supporting patients with specific forms of muscle spasticity and excessive drooling (sialorrhea).

Parkines is relevant when supportive symptom management is appropriate, particularly applied during phases when symptoms become more noticeable. By helping to moderate symptoms related to physical discomfort, it provides support that helps ease the overall symptom burden and may assist with maintaining functional stability.

“It is used in situations involving certain distressing symptoms that interfere with daily functioning.”

Quick Fact: Relief for Motor Rigidity Parkines is considered relevant to help with symptoms related to physical discomfort and functional strain caused by muscle stiffness in various forms of parkinsonism.

Regulatory References

  1. NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Parkines?

Eligibility for Parkines (Trihexyphenidyl hydrochloride) is determined by official regulatory documents based on patient population, age, and pre-existing conditions. The primary patient population for use is adults.

Contraindications (Must Not Use)

Use is strictly contraindicated in patients with a known hypersensitivity to the drug or any of its ingredients. It is also prohibited for individuals with narrow angle glaucoma (angle-closure glaucoma).

Population Restrictions and Cautions

  • Pediatric Use: Use is not recommended as safety and efficacy have not been established in children.
  • Older Adults (Geriatric): Use requires strict dosage regulation and close observation due to increased sensitivity to the drug’s effects.
  • Organ Function: Patients with cardiac disorders, hypertension, renal impairment, or hepatic impairment must be closely monitored.
  • Obstructive Conditions: Caution is required in patients with obstructive disease of the gastrointestinal or genitourinary tracts and in cases of prostatic hypertrophy.
  • Life Stage: Use during pregnancy and lactation is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Trihexyphenidyl (Parkines) is largely defined by its function as a central anticholinergic agent, resulting in predictable pharmacodynamic effects when co-administered with certain medicinal products and substances.

Documented Interaction Patterns

Additive Anticholinergic Effects: Co-administration with other drugs that possess anticholinergic properties can lead to an intensification of these effects. This pharmacodynamic interaction is documented with Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), and other Parasympathetic Inhibitors.

Additive Central Nervous System (CNS) Depression: The use of Trihexyphenidyl concurrently with CNS Depressants, including Alcohol, may result in increased sedative outcomes. The combination with substances like Cannabinoids and Opiates is officially noted in the regulatory context of additive effects.

Exposure and Antagonistic Effects: Trihexyphenidyl may possibly reduce the absorption of Levodopa, and co-administration often requires a reduction in the usual dose of each drug. Furthermore, Trihexyphenidyl is formally antagonistic to the gastrointestinal actions of prokinetic agents such as Metoclopramide and Domperidone.

Population and Condition-Specific Constraints

Administration to the chronically ill, alcoholics, or those with central nervous system disease requires caution in hot weather. When co-administered with other atropine-like drugs in these conditions, there is a documented risk of hyperthermia.

Mechanism of Action

Dopamine Precursor Delivery and Central Replenishment

The mechanism of Parkines centers on the use of levodopa ( L-DOPA), a metabolic precursor to dopamine. Levodopa is transported across the blood-brain barrier and is converted into active dopamine within the central nervous system by the enzyme Aromatic L-amino acid decarboxylase (AADC). This increased central dopamine concentration promotes the engagement of post-synaptic dopaminergic receptors, thereby enhancing signal transmission within the basal ganglia circuitry.


Peripheral Enzyme Inhibition and Optimized Bioavailability

Carbidopa and entacapone function as peripheral enzyme inhibitors to regulate levodopa pharmacokinetics. Carbidopa acts in peripheral tissues to inhibit AADC, which blocks the premature conversion of levodopa to dopamine outside the brain. Entacapone, a peripheral inhibitor of Catechol-O-Methyltransferase (COMT), blocks an alternative degradation pathway, thus prolonging the systemic half-life of levodopa. These combined actions modify the levodopa kinetic profile, increasing its concentration and sustained delivery to the central site of action.


Influencing Dopaminergic Signaling Cascades

The subsequent rise in central dopamine concentration initiates signaling cascades that regulate the electrical and chemical activity within the motor circuits. The sustained signal transduction within the dopaminergic pathways results from the collective action of precursor supply and enzymatic protection.

Dosage and Administration Information

How Parkines is Used: Official Administration and Dosing Principles

Parkines (Trihexyphenidyl hydrochloride) is an oral medication available as both tablets (typically 2 mg and 5 mg strengths) and an elixir for administration via the oral route. The administration protocol is centered on individualized dose titration to find the minimal effective amount.


Official Dosing and Schedule

Administration is generally conducted in divided doses, typically three or four times daily. For higher total daily doses, the intake may be split into four portions, taken at mealtimes and at bedtime.

Usage Scenario Starting Dose Maintenance Range (Total Daily)
Parkinsonism 1 mg once daily 6 to 10 mg
Drug-Induced EPS 1 mg single dose 5 to 15 mg

Dosage increases are made gradually, in increments of 2 mg, at intervals of three to five days. The total daily intake should not exceed 15 mg for most approved uses.


Contextual Use and Adjustments

Parkines may be taken before or after meals. Taking the dose before meals is sometimes used to manage excessive dry mouth, while taking it after meals is suggested if nausea occurs. When transitioning from another similar medication, Parkines is introduced with a partial substitution while the dose of the former agent is progressively reduced.

For older adults (over 60), the initial dose is generally kept low, and subsequent increases are cautious, emphasizing the use of the lowest effective dose. Abrupt discontinuation of this medication is advised against.

Recent Clinical Evidence

Research evidence / Overview of studies for Parkines

Evidence for Use in Parkinson's Disease (Parkinsonism)

Research exploring the use of Parkines (Trihexyphenidyl) in Parkinson's disease has been documented through studies spanning many years, including controlled trials and observational reports. These studies primarily examined how outcomes related to key motor symptoms, such as tremor and rigidity (stiffness), were measured in adult populations. Historically, studies explored measured outcomes related to symptoms like tremor and stiffness. When research examined the use of Parkines combined with levodopa, some controlled studies explored whether the addition resulted in further measured change; evidence quality varies across studies. The core evidence is older, and long-term effects are not fully established in the context of modern treatment approaches.

Evidence for Managing Drug-induced Movement Disorders (EPS)

Parkines was evaluated in studies focusing on research exploring short-term symptom changes in populations with movement problems caused by other medications, known as Extrapyramidal Symptoms (EPS). The evidence base consists of controlled studies, systematic reviews, and post-marketing data referenced by major regulatory bodies. Studies observed patterns related to changes in symptoms during episodes where symptoms become more noticeable, particularly for acute dystonia and drug-induced parkinsonism. Uncertainty remains regarding which patients may benefit from receiving the compound proactively versus those who use it only when symptoms are actively occurring.

Evidence in Specific Dystonia and Sialorrhea and Key Research Gaps

The compound was studied for some specific forms of movement disorders, including dystonia in certain chronic neurological conditions and excessive drooling (sialorrhea). The evidence for these uses is generally derived from small prospective studies and systematic reviews. The sample sizes were modest across several key trials, meaning that certainty remains low regarding the consistency of the observed outcomes in these groups.

Research on Parkines in special populations notes specific challenges. Evidence describes patterns related to lower study completion rates in some older adults. For children, results apply only to the specific, often small, populations studied. The overall evidence quality varies across studies, and comparative evidence is lacking against the newest classes of medications used today.

Key Studies & References

  1. Trihexyphenidyl Hydrochloride Oral Tablets: Official Labeling and Monograph

Frequently Asked Questions (FAQ)

Common questions about Parkines (FAQ)

Q: Is Parkines considered a long-term medication?

The medication’s official labeling notes that its use may continue indefinitely in some instances. However, because it has atropine-like properties, the labeling also states that patients on long-term treatment should be subjected to constant and careful observation by a healthcare professional.

Q: What is the difference between Parkines and other similar treatments I've heard about?

Parkines (Trihexyphenidyl hydrochloride) is classified as a synthetic anticholinergic agent, which is a type of antispasmodic drug. This classification means the medication has properties similar to atropine, and its associated side effects are generally noted in official documents as being less frequent and less severe than those of atropine.

Q: Why might a doctor switch a patient from one medicine to Parkines?

According to official information, Parkines is indicated for controlling specific movement disorders, known as extrapyramidal symptoms (EPS), that are caused by other central nervous system (CNS) medications. It is also often used as an add-on therapy when addressing Parkinsonism in patients who are already receiving levodopa.

Q: Does Parkines affect sleep patterns?

Official safety data indicates that sleep may be affected by this medication. Adverse reactions such as insomnia (trouble sleeping) and restlessness have been reported in patients using Parkines.

Q: What are the general expectations for someone starting Parkines?

The total dose is determined individually and is started low, then gradually increased to find the most effective amount. Studies show that minor side effects such as dry mouth or dizziness are commonly experienced by 30 to 50 percent of all patients. The medication is intended to help modulate nerve signals and is used to address symptoms like muscle control issues and stiffness.

Q: How do drug-drug interactions with Parkines typically show up?

Combining this medication with alcohol or other CNS depressants may result in increased sedative outcomes. Additionally, official warnings note that when Parkines is taken with other similar anticholinergic drugs, especially in hot weather, there is a risk of hyperthermia (dangerously high body temperature) due to the inability to sweat.

Q: How quickly can I expect to notice any effects from Parkines?

Pharmacological information indicates that the onset of action is reported to be about 60 minutes after taking an oral dose. The medication typically reaches its peak activity level in the body after approximately two hours.

Q: Do I need to change my diet while using Parkines?

Regulatory guidance states that unless a healthcare professional provides specific instructions otherwise, a patient can generally maintain their normal diet while using this medication. The dose is sometimes taken relative to meals to help manage specific side effects like dry mouth or nausea.

Q: How long does Parkines stay in your system after stopping it?

The estimated elimination half-life is the time required for the concentration of the medication in the body to reduce by half. This period is generally reported to be between 5 to 10 hours, although some pharmacological data suggests it may take longer in certain individuals.

Q: What should I do if I forget to take my Parkines dose?

Official product instructions state that if a dose is missed, the medication is to be taken as soon as it is remembered. However, if the time is almost right for the next scheduled dose, the regulation indicates that the missed dose should be bypassed. The instructions also advise against doubling the dose to compensate for a forgotten one.

Q: Is Parkines habit-forming or addictive?

Parkines is not currently classified by the government as a controlled substance. However, official documents caution that there is a potential for abuse that should be considered due to its stimulant-like and euphoriant properties.

Q: What happens if I miss several doses of Parkines?

Official warnings indicate that abrupt withdrawal or a sudden, rapid reduction in dose is advised against due to the risk of severe symptom worsening. Furthermore, sudden stopping has been associated with a potentially fatal condition known as Neuroleptic Malignant Syndrome (NMS).

Q: Can Parkines be crushed or split if it's a tablet?

Some official resources suggest that the tablet form can be crushed and mixed with a small amount of soft food, such as jam or yogurt, for easier consumption. Official guidance notes that if this method is used, the mixture is to be swallowed immediately without chewing. Patients are instructed to confirm specific administration methods with their prescribing physician or pharmacist.

Q: Is Parkines available as a generic version?

Regulatory records indicate that the original brand name of this medication has been discontinued. The medication is now typically available only in its generic form, which is Trihexyphenidyl hydrochloride.

Q: Can I drive or operate machinery while taking Parkines?

Official warnings state that this medication may impair physical or mental abilities due to side effects like dizziness, confusion, or blurred vision. Regulatory warnings state that patients must be cautious about performing tasks that require mental alertness, such as driving or operating hazardous machinery, until they know the medication's effects.

Q: Is Parkines a common treatment for the condition it addresses?

While the medication is officially indicated for Parkinsonism and drug-induced movement disorders, clinical standing indicates it is generally not used as a first-line treatment. Regulatory and historical reviews note that it has largely been replaced by newer medication classes, such as levodopa.

How should Parkines be stored and disposed of?

How to Store and Dispose of Parkines (Trihexyphenidyl)

The storage and disposal of Trihexyphenidyl hydrochloride tablets must strictly follow regulatory guidance to maintain product quality and public safety.

Storage Requirement Official Condition
Temperature Store below 25 C (e.g., at Controlled Room Temperature).
Protection Keep in the original container and protect from moisture.
Container Rule Keep the container tightly closed to shield the tablets from the environment.

Storage must be maintained out of the sight and reach of children to prevent accidental ingestion. When the medicine is no longer needed, disposal should be done by consulting a pharmacist or healthcare professional for instructions. The unused product must be disposed of in compliance with applicable local regulations, and should not be discarded via wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Parkines found in:

A-Z Index: